PDF / 30 KB 
collectBayerNews_20091119_0695_en.pdf BayerNews_20091119_0695_en.pdf
Endpoints met in EINSTEIN-Extension Trial in the Secondary Prevention of Recurrent Symptomatic VTE
Berlin, November 19, 2009 - Findings from the Phase III EINSTEIN-Extension
study will be presented in the Late Breaking Abstract Session on December 8,
2009, (7:45 am CST, Hall F, Ernest N. Morial Convention Center) at the 51st
Annual Meeting of the American Society of Hematology (ASH) in New Orleans,
Louisiana.
The study investigated the long-term benefits of 20 mg rivaroxaban once-daily
compared with placebo in the secondary prevention of recurrent symptomatic
venous blood clots in approximately 1,200 patients with symptomatic deep vein
thrombosis (DVT) or pulmonary embolism (PE). These patients had already
completed 6 or 12 months of anticoagulant therapy, either as part of their
routine care for an acute episode of venous thromboembolism (VTE) or as a
participant in the EINSTEIN-DVT or EINSTEIN-PE clinical trials, where patients
received either rivaroxaban or a vitamin K antagonist.
The abstract (lba-2) is available online at the ASH website:
www.hematology.org/Meetings/Annual-meeting/.
About EINSTEIN
EINSTEIN is a global clinical development program of three trials in
approximately 8,000 patients. Two of these studies enrolled patients with
acute, symptomatic deep vein thrombosis (EINSTEIN-DVT, enrollment complete) or
pulmonary embolism (EINSTEIN-PE). In these two programs, patients received oral
rivaroxaban 15 mg twice-daily for three weeks, followed by oral rivaroxaban 20
mg once-daily, compared with initial enoxaparin treatment followed by a vitamin
K antagonist. The third study, EINSTEIN-Extension, was designed to evaluate the
long-term benefits of rivaroxaban treatment in the secondary prevention of
recurrent symptomatic VTE versus placebo.
New Findings Reinforce Landmark Results from RECORD Program Rivaroxaban, a
novel oral, direct Factor Xa inhibitor, consistently demonstrated superior
efficacy over enoxaparin, whilst maintaining a similar safety profile, in the
Phase III RECORD clinical trial program. The aim of the RECORD program was to
evaluate rivaroxaban in the prevention of VTE following elective total hip or
knee replacement surgery. Results of the RECORD1, 2 and 3 trials were presented
at ASH in 2007.
About rivaroxaban
Rivaroxaban was invented in Bayer's Wuppertal laboratories in Germany, and is
being jointly developed by Bayer HealthCare and Johnson & Johnson
Pharmaceutical Research & Development, L.L.C. Rivaroxaban is marketed under the
brand name Xarelto®, and approvals have been granted for the prevention of VTE
in adult patients undergoing elective hip or knee replacement surgery in over
80 countries, including the EU, Australia, Canada, China and Mexico. To date,
Xarelto® has been launched in more than 50 countries around the world by Bayer
HealthCare.
The extensive clinical trial program supporting rivaroxaban makes it the most
studied oral, direct Factor Xa inhibitor in the world today. More than 65,000
patients are expected to be enrolled into the rivaroxaban clinical development
program, which will evaluate the product in the prevention and treatment of a
broad range of acute and chronic blood-clotting disorders, including VTE
treatment, stroke prevention in patients with atrial fibrillation, secondary
prevention of acute coronary syndrome, and VTE prevention in hospitalized,
medically ill patients.
To learn more about thrombosis, please visit www.thrombosisadviser.com
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of
health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary
of Bayer AG, is one of the world's leading, innovative companies in the
healthcare and medical products industry and is based in Leverkusen, Germany.
The company combines the global activities of the Animal Health, Bayer Schering
Pharma, Consumer Care and Medical Care divisions. Bayer HealthCare's aim is to
discover and manufacture products that will improve human and animal health
worldwide. Find more information at www.bayerhealthcare.com.
About Bayer Schering Pharma
Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company.
Its research and business activities are focused on the following areas:
Diagnostic Imaging, General Medicine, Specialty Medicine and Women's
Healthcare. With innovative products, Bayer Schering Pharma aims for leading
positions in specialized markets worldwide. Using new ideas, Bayer Schering
Pharma aims to make a contribution to medical progress and strives to improve
the quality of life.
Find more information at www.bayerscheringpharma.de.
